Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis

Date: November 30, 2012
Pages: 35
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FE2997DDF61EN
Leaflet:

Download PDF Leaflet

Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis
Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Fluad is a trivalent, inactivated influenza vaccine that contains MF59 adjuvant, an oil-in-water emulsion containing squalene, polysorbate 80, and sorbitan trioleate. The virus strains present in the vaccine are grown in chicken eggs, harvested via centrifugation, inactivated with formaldehyde, and the surface antigens are purified via further centrifugation. The vaccine is indicated for immunization against seasonal influenza via intramuscular injection, and the MF59 adjuvant boosts the immune response of the recipient. Fluad was designed to improve the efficacy of influenza vaccines in elderly patients, who have waning immune systems. Fluad is marketed by Novartis in numerous European and Asian counties, including France, German, Spain, and China.

Scope
  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Fluad including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Fluad for the top five countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy and Spain
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fluad performance
  • Obtain sales forecast for Fluad from 2012 to 2022 in the US, France, Germany, Italy and Spain.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis

4 DISEASE MANAGEMENT

4.1 Influenza Vaccination Policy

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile - Fluad
  5.3.1 Overview
  5.3.2 Efficacy
  5.3.3 Safety
  5.3.4 SWOT Analysis
  5.3.5 Forecast

6 APPENDIX

6.1 Bibliography
6.2 Abbreviations
6.3 Methodology
6.4 Forecasting Methodology
  6.4.1 Vaccine Coverage
  6.4.2 Influenza Vaccine Tender System Assumptions
  6.4.3 General Pricing Assumptions
  6.4.4 Individual Vaccine Assumptions
6.5 Physicians and Specialists Included in this Study
6.6 Primary Research - Prescriber Survey
6.7 About the Authors
  6.7.1 Authors
  6.7.2 Global Head of Healthcare
6.8 About GlobalData
6.9 Contact Us
6.10 Disclaimer

LIST OF TABLES

Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Product Profile - Fluad
Table 7: Fluad SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for Fluad, 2012-2022
Table 9: Physicians Surveyed, By Country

LIST OF FIGURES

Figure 1: Influenza Virus Structure

Ask Your Question

Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: